Published in NeuroRx on January 01, 2006
Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 1.19
From attention to memory along the dorsal-ventral axis of the medial prefrontal cortex: some methodological considerations. Front Syst Neurosci (2014) 0.90
Finding what you are not looking for: strategies for developing novel treatments in psychiatry. NeuroRx (2006) 0.82
COMT polymorphism modulates the resting-state EEG alpha oscillatory response to acute nicotine in male non-smokers. Genes Brain Behav (2015) 0.75
Neural mechanisms of selective visual attention. Annu Rev Neurosci (1995) 24.99
Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A (2001) 9.42
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature (1996) 7.26
Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet (2004) 5.70
Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature (1995) 5.63
Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry (1986) 4.34
Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A (2003) 4.21
Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem (1958) 4.16
Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry (1995) 4.10
Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A (1998) 3.99
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry (2002) 3.89
A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev (1997) 3.80
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology (2002) 3.79
Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex (2000) 3.37
Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry (1992) 3.02
Dopaminergic role in stimulant-induced wakefulness. J Neurosci (2001) 2.91
Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci (2002) 2.69
Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol Psychiatry (2000) 2.68
Selection, integration, and conflict monitoring; assessing the nature and generality of prefrontal cognitive control mechanisms. Neuron (2004) 2.50
Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature (1997) 2.46
Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci (2002) 2.46
Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry (2001) 2.45
Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry. Proc Natl Acad Sci U S A (1996) 2.40
Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. Arch Gen Psychiatry (1998) 2.28
Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci (2000) 2.18
Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biol Psychiatry (1999) 2.17
Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) (2002) 2.17
Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) (1994) 2.09
Cognition and control in schizophrenia: a computational model of dopamine and prefrontal function. Biol Psychiatry (1999) 2.08
Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology (Berl) (1997) 2.08
Effects of bromocriptine on human subjects depend on working memory capacity. Neuroreport (1997) 2.00
The role of the regulatory enzymes of catecholamine synthesis in Parkinson's disease. Neurology (1992) 1.99
The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull (1999) 1.99
Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J Comp Neurol (2001) 1.95
Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science (2000) 1.91
Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev (1975) 1.79
The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol (1994) 1.76
Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr Clin North Am (2005) 1.63
Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage (2000) 1.63
Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther (1990) 1.60
Catecholamine regulation of the prefrontal cortex. J Psychopharmacol (1997) 1.59
Selective activation of mesocortical DA system by stress. Nature (1976) 1.56
The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry (1999) 1.56
Functional magnetic resonance imaging brain mapping in psychiatry: methodological issues illustrated in a study of working memory in schizophrenia. Neuropsychopharmacology (1998) 1.54
Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia. Brain Res Brain Res Rev (2000) 1.51
Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci (2002) 1.51
Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits. Proc Natl Acad Sci U S A (2001) 1.51
Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem (1990) 1.51
Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol (1999) 1.50
Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1----q11.2. Genomics (1992) 1.49
Effect of noxious tail pinch on the discharge rate of mesocortical and mesolimbic dopamine neurons: selective activation of the mesocortical system. Brain Res (1989) 1.45
An NMDA intervention strategy in schizophrenia with "low-dose" milacemide. Clin Neuropharmacol (1991) 1.41
Hedonic valence, dopamine and motivation. Mol Psychiatry (1996) 1.39
Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry (1997) 1.39
Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry (1998) 1.35
Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Res (2002) 1.33
Catechol O-methyltransferase (COMT) mRNA expression in the dorsolateral prefrontal cortex of patients with schizophrenia. Neuropsychopharmacology (2003) 1.30
Pharmacology of mesocortical dopamine neurons. Pharmacol Rev (1983) 1.27
Enhancement by an ampakine of memory encoding in humans. Exp Neurol (1997) 1.24
Cloning, expression and structure of catechol-O-methyltransferase. Biochim Biophys Acta (1995) 1.24
The effects of prefrontal lesions on working memory performance and theory. Cogn Affect Behav Neurosci (2004) 1.24
Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form. Proc Natl Acad Sci U S A (1991) 1.23
The anatomy of dopamine in monkey and human prefrontal cortex. J Neural Transm Suppl (1992) 1.23
Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons. Neuroscience (1984) 1.22
Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology (Berl) (2004) 1.22
Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. Eur J Pharmacol (1990) 1.20
A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther (1982) 1.18
Dextroamphetamine enhances "neural network-specific" physiological signals: a positron-emission tomography rCBF study. J Neurosci (1996) 1.18
The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology (1999) 1.17
Interaction between diffusion and Michaelis-Menten uptake of dopamine after iontophoresis in striatum. Biophys J (1995) 1.17
The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci (1991) 1.17
Evoked extracellular dopamine in vivo in the medial prefrontal cortex. J Neurochem (1993) 1.15
Molecular cloning and characterization of rat liver catechol-O-methyltransferase. Gene (1990) 1.14
Probing prefrontal function in schizophrenia with neuropsychological paradigms. Schizophr Bull (1988) 1.13
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry (1995) 1.13
Effects of pergolide on intravenous cocaine self-administration in men and women. Psychopharmacology (Berl) (1998) 1.12
How antipsychotics work-from receptors to reality. NeuroRx (2006) 1.12
Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport (2001) 1.11
Attenuated frontal activation during a verbal fluency task in patients with schizophrenia. Am J Psychiatry (1998) 1.10
Genetics of red cell COMT activity: analysis of thermal stability and family data. Am J Med Genet (1981) 1.09
Catechol-O-methyltransferase activity: a determinant of levodopa response. Clin Pharmacol Ther (1980) 1.07
Cognitive improvement during Tolcapone treatment in Parkinson's disease. J Neural Transm (Vienna) (1997) 1.07
Microdomains for dopamine volume neurotransmission in primate prefrontal cortex. J Neurosci (2004) 1.05
The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol (1993) 1.05
Catecholamine release and uptake in the mouse prefrontal cortex. J Neurochem (2001) 1.04
Neuropsychiatric dynamics: the study of mental illness using functional magnetic resonance imaging. Eur J Radiol (1999) 1.04
Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm Suppl (1990) 1.04
A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) (2004) 1.01
Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol (1991) 0.99
First evidence of a delay-dependent working memory-enhancing effect of modafinil in mice. Neuroreport (2001) 0.99
Analysis of alpha-2 adrenergic agonist effects on the delayed nonmatch-to-sample performance of aged rhesus monkeys. Neurobiol Aging (1991) 0.98
Idiopathic hypersomnia. Psychiatry Clin Neurosci (1998) 0.98
Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Behav Brain Res (1997) 0.97
The catecholaminergic innervation of primate prefrontal cortex. J Neural Transm Suppl (1992) 0.96
Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition. J Neurosci (2001) 0.96
Regional cerebral blood flow in monozygotic twins discordant and concordant for schizophrenia. Arch Gen Psychiatry (1992) 0.95
Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat. Brain Res (1992) 0.95
Distinct pharmacological regulation of evoked dopamine efflux in the amygdala and striatum of the rat in vivo. Synapse (1995) 0.93
18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse (2002) 0.92
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell (2003) 12.50
5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci (2005) 10.13
Serotonin transporter genetic variation and the response of the human amygdala. Science (2002) 9.31
Spatio-temporal transcriptome of the human brain. Nature (2011) 9.19
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry (2005) 6.27
Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet (2004) 5.70
Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci (2006) 5.70
Hierarchical organization of human cortical networks in health and schizophrenia. J Neurosci (2008) 5.19
Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci (2003) 5.11
Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature (2011) 5.01
The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci (2004) 4.84
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry (2004) 4.46
A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry (2005) 4.33
Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A (2003) 4.21
The amygdala response to emotional stimuli: a comparison of faces and scenes. Neuroimage (2002) 3.70
Neural mechanisms of genetic risk for impulsivity and violence in humans. Proc Natl Acad Sci U S A (2006) 3.58
Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am J Psychiatry (2003) 3.52
Neocortical modulation of the amygdala response to fearful stimuli. Biol Psychiatry (2003) 3.43
Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genet (2008) 3.33
Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry (2006) 3.24
DNA methylation signatures in development and aging of the human prefrontal cortex. Am J Hum Genet (2012) 3.17
Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A (2002) 3.11
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03
Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry (2003) 2.82
Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch Gen Psychiatry (2005) 2.78
Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. Proc Natl Acad Sci U S A (2005) 2.73
Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. Proc Natl Acad Sci U S A (2006) 2.71
Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci U S A (2005) 2.68
A validated network of effective amygdala connectivity. Neuroimage (2007) 2.58
Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci (2004) 2.50
Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry (2003) 2.47
Imaging genomics. Br Med Bull (2003) 2.39
Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci (2005) 2.39
Effect of catechol-O-methyltransferase val158met genotype on attentional control. J Neurosci (2005) 2.37
Efficient physical embedding of topologically complex information processing networks in brains and computer circuits. PLoS Comput Biol (2010) 2.37
A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat Med (2009) 2.37
Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A (2004) 2.36
Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci (2002) 2.32
Imaging genetics: perspectives from studies of genetically driven variation in serotonin function and corticolimbic affective processing. Biol Psychiatry (2006) 2.29
Genetic variation in CACNA1C affects brain circuitries related to mental illness. Arch Gen Psychiatry (2010) 2.28
Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet (2006) 2.21
A common allele in the oxytocin receptor gene (OXTR) impacts prosocial temperament and human hypothalamic-limbic structure and function. Proc Natl Acad Sci U S A (2010) 2.16
Prenatal expression patterns of genes associated with neuropsychiatric disorders. Am J Psychiatry (2014) 2.14
Variation in dopamine genes influences responsivity of the human reward system. Proc Natl Acad Sci U S A (2008) 2.13
Age-related alterations in default mode network: impact on working memory performance. Neurobiol Aging (2008) 2.11
Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J Neurosci (2008) 2.08
Cognitive fitness of cost-efficient brain functional networks. Proc Natl Acad Sci U S A (2009) 2.07
Neurophysiological correlates of age-related changes in working memory capacity. Neurosci Lett (2005) 2.06
Genes and the parsing of cognitive processes. Trends Cogn Sci (2004) 1.97
Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet (2004) 1.95
Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. Arch Gen Psychiatry (2006) 1.94
Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol (2002) 1.87
Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in human brain. J Neurosci (2006) 1.85
Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling. Hum Mol Genet (2006) 1.82
Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry (2004) 1.82
Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci (2003) 1.82
Catechol-O-methyltransferase Val158Met modulation of prefrontal-parietal-striatal brain systems during arithmetic and temporal transformations in working memory. J Neurosci (2007) 1.81
DISC1 splice variants are upregulated in schizophrenia and associated with risk polymorphisms. Proc Natl Acad Sci U S A (2009) 1.76
Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res (2002) 1.76
Widespread reductions of cortical thickness in schizophrenia and spectrum disorders and evidence of heritability. Arch Gen Psychiatry (2009) 1.75
Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest (2007) 1.74
Is gray matter volume an intermediate phenotype for schizophrenia? A voxel-based morphometry study of patients with schizophrenia and their healthy siblings. Biol Psychiatry (2007) 1.73
Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology (2006) 1.71
Prefrontal-hippocampal coupling during memory processing is modulated by COMT val158met genotype. Biol Psychiatry (2006) 1.71
Dysfunctional prefrontal regional specialization and compensation in schizophrenia. Am J Psychiatry (2006) 1.69
Quantifying incoherence in speech: an automated methodology and novel application to schizophrenia. Schizophr Res (2007) 1.68
Association of the SerCys DISC1 polymorphism with human hippocampal formation gray matter and function during memory encoding. Eur J Neurosci (2008) 1.67
False positives in imaging genetics. Neuroimage (2007) 1.65
Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex (2007) 1.62
Normal age-related brain morphometric changes: nonuniformity across cortical thickness, surface area and gray matter volume? Neurobiol Aging (2010) 1.62
Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia. J Neurosci (2011) 1.61
Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. Hum Mol Genet (2006) 1.61
Interactive effects of DAOA (G72) and catechol-O-methyltransferase on neurophysiology in prefrontal cortex. Biol Psychiatry (2011) 1.58
Genetic variation in KCNH2 associated with expression in the brain of a unique hERG isoform modulates treatment response in patients with schizophrenia. Am J Psychiatry (2012) 1.57
Prefrontal broadband noise, working memory, and genetic risk for schizophrenia. Am J Psychiatry (2004) 1.57
Variation of human amygdala response during threatening stimuli as a function of 5'HTTLPR genotype and personality style. Biol Psychiatry (2005) 1.55
Absence of regional brain volume change in schizophrenia associated with short-term atypical antipsychotic treatment. Schizophr Res (2007) 1.54
Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proc Natl Acad Sci U S A (2007) 1.53
Schizophrenia drug says goodbye to dopamine. Nat Med (2007) 1.53
Amphetamine modulates human incentive processing. Neuron (2004) 1.52
Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry (2004) 1.51
MicroSNiPer: a web tool for prediction of SNP effects on putative microRNA targets. Hum Mutat (2010) 1.51
Brain regions underlying response inhibition and interference monitoring and suppression. Eur J Neurosci (2006) 1.51
Interactive effect of apolipoprotein e genotype and age on hippocampal activation during memory processing in healthy adults. Arch Gen Psychiatry (2012) 1.48
Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia. Cell (2012) 1.48
No effect of a common allelic variant in the reelin gene on intermediate phenotype measures of brain structure, brain function, and gene expression. Biol Psychiatry (2010) 1.48
Habit and skill learning in schizophrenia: evidence of normal striatal processing with abnormal cortical input. Learn Mem (2002) 1.48
Heritability of brain morphology related to schizophrenia: a large-scale automated magnetic resonance imaging segmentation study. Biol Psychiatry (2007) 1.45
Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization. J Neurosci (2007) 1.44
Neural mechanisms underlying probabilistic category learning in normal aging. J Neurosci (2005) 1.43
Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest (2008) 1.43
Molecular cloning of a brain-specific, developmentally regulated neuregulin 1 (NRG1) isoform and identification of a functional promoter variant associated with schizophrenia. J Biol Chem (2007) 1.41
Genetic variation in catechol-O-methyltransferase: effects on working memory in schizophrenic patients, their siblings, and healthy controls. Biol Psychiatry (2007) 1.41
Neonatal hippocampal damage alters electrophysiological properties of prefrontal cortical neurons in adult rats. Cereb Cortex (2002) 1.40
The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr Res (2013) 1.38
Altered cortical network dynamics: a potential intermediate phenotype for schizophrenia and association with ZNF804A. Arch Gen Psychiatry (2011) 1.38
Dopamine modulates the response of the human amygdala: a study in Parkinson's disease. J Neurosci (2002) 1.38
Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum Mol Genet (2008) 1.36
Common genetic variation in Neuregulin 3 (NRG3) influences risk for schizophrenia and impacts NRG3 expression in human brain. Proc Natl Acad Sci U S A (2010) 1.36